Nociceptive neurons express preferentially certain sodium channel isoforms that are critical for their particular neuronal excitability in health and disease. Their expression and functional properties of voltage-gated sodium channels are dynamically altered after axonal injury and inflammation. In this regard, several sodium channels have been proposed as potential targets for pain therapeutics.
21,22 In particular, Nav 1.3 expression is augmented after sciatic nerve axotomy,
20,41 whereas inflammatory modulators such as prostaglandin E2, adenosine, and 5-hydroxytryptamine increase tetrodotoxin-resistant sodium currents,
42,43 and the intraplantar injection of carrageenan upregulates the expression of Nav 1.8 transcripts in rat nociceptive DRG neurons.
44 Additionally, in transgenic mice lacking any of the three sodium channels that are expressed selectively in peripheral damage-sensing neurons from the trigeminal ganglia and dorsal root ganglia, namely, Nav 1.7, 1.8, and 1.9, thermal and mechanical hyperalgesia by the intraplantar injection of inflammatory agents is drastically decreased,
45–47 suggesting a major role for these sodium channel isoforms in the nociceptor sensitization associated with peripheral inflammation at the injury site. Of note, lidocaine, carbamazepine, and amitriptyline have been reported to inhibit all the aforementioned Nav channel subtypes expressed by nociceptors.
30,34,48–50 In addition, in corneal nociceptive nerve terminals, functional evidence suggests that tetrodotoxin-resistant sodium currents are the primary determinant of their excitability,
51 which leads to the presumption that tetrodotoxin-resistant sodium channels are the main contributors to the onset of membrane hyperexcitability in corneal nociceptive terminals after injury, and in turn they are the main molecular targets of the sodium channel blockers assessed in this work.